These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32995778)

  • 1. Neutralization Assay with SARS-CoV-1 and SARS-CoV-2 Spike Pseudotyped Murine Leukemia Virions.
    Zheng Y; Larragoite ET; Lama J; Cisneros I; Delgado JC; Slev P; Rychert J; Innis EA; Williams ESCP; Coiras M; Rondina MT; Spivak AM; Planelles V
    bioRxiv; 2020 Sep; ():. PubMed ID: 32995778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions.
    Zheng Y; Larragoite ET; Williams ESCP; Lama J; Cisneros I; Delgado JC; Slev P; Rychert J; Innis EA; Coiras M; Rondina MT; Spivak AM; Planelles V
    Virol J; 2021 Jan; 18(1):1. PubMed ID: 33397387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera.
    Oguntuyo KY; Stevens CS; Hung CT; Ikegame S; Acklin JA; Kowdle SS; Carmichael JC; Chiu HP; Azarm KD; Haas GD; Amanat F; Klingler J; Baine I; Arinsburg S; Bandres JC; Siddiquey MNA; Schilke RM; Woolard MD; Zhang H; ; Duty AJ; Kraus TA; Moran TM; Tortorella D; Lim JK; Gamarnik AV; Hioe CE; Zolla-Pazner S; Ivanov SS; Kamil JP; Krammer F; Lee B
    mBio; 2021 Feb; 12(1):. PubMed ID: 33593976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization.
    Wohlgemuth N; Whitt K; Cherry S; Kirkpatrick Roubidoux E; Lin CY; Allison KJ; Gowen A; Freiden P; Allen EK; ; Gaur AH; Estepp JH; Tang L; Mori T; Hijano DR; Hakim H; McGargill MA; Krammer F; Whitt MA; Wolf J; Thomas PG; Schultz-Cherry S
    Microbiol Spectr; 2021 Oct; 9(2):e0105921. PubMed ID: 34704832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and effectiveness of pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test
    Yang R; Huang B; A R; Li W; Wang W; Deng Y; Tan W
    Biosaf Health; 2020 Dec; 2(4):226-231. PubMed ID: 32864605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein.
    Tani H; Kimura M; Tan L; Yoshida Y; Ozawa T; Kishi H; Fukushi S; Saijo M; Sano K; Suzuki T; Kawasuji H; Ueno A; Miyajima Y; Fukui Y; Sakamaki I; Yamamoto Y; Morinaga Y
    Virol J; 2021 Jan; 18(1):16. PubMed ID: 33435994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity.
    Zhang F; Schmidt F; Muecksch F; Wang Z; Gazumyan A; Nussenzweig MC; Gaebler C; Caskey M; Hatziioannou T; Bieniasz PD
    mBio; 2024 Feb; 15(2):e0167223. PubMed ID: 38193662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.
    O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR
    Front Immunol; 2023; 14():1055429. PubMed ID: 36845123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays.
    Crawford KHD; Eguia R; Dingens AS; Loes AN; Malone KD; Wolf CR; Chu HY; Tortorici MA; Veesler D; Murphy M; Pettie D; King NP; Balazs AB; Bloom JD
    Viruses; 2020 May; 12(5):. PubMed ID: 32384820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays.
    Valdivia A; Torres I; Latorre V; Francés-Gómez C; Albert E; Gozalbo-Rovira R; Alcaraz MJ; Buesa J; Rodríguez-Díaz J; Geller R; Navarro D
    Eur J Clin Microbiol Infect Dis; 2021 Mar; 40(3):485-494. PubMed ID: 33404891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Murine Leukemia Virus (MLV)-based Coronavirus Spike-pseudotyped Particle Production and Infection.
    Millet JK; Whittaker GR
    Bio Protoc; 2016 Dec; 6(23):. PubMed ID: 28018942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoplasmic Tail Truncation of SARS-CoV-2 Spike Protein Enhances Titer of Pseudotyped Vectors but Masks the Effect of the D614G Mutation.
    Chen HY; Huang C; Tian L; Huang X; Zhang C; Llewellyn GN; Rogers GL; Andresen K; O'Gorman MRG; Chen YW; Cannon PM
    J Virol; 2021 Oct; 95(22):e0096621. PubMed ID: 34495700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development and application of a safe SARS-CoV neutralization assay based on lentiviral vectors pseudotyped with SARS-CoV spike protein].
    Yan KX; Tan WJ; Zhang XM; Wang HJ; Li Y; Ruan L
    Bing Du Xue Bao; 2007 Nov; 23(6):440-6. PubMed ID: 18092680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals.
    Stelitano D; Weisberg SP; Goldklang MP; Zhu Y; Bovier FT; Kalantarov GF; Greco G; Decimo D; Franci G; Cennamo M; Portella G; Galdiero M; Mathieu C; Horvat B; Trakht IN; Moscona A; Whitt MA; Porotto M
    mSphere; 2021 Aug; 6(4):e0057121. PubMed ID: 34319126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein.
    Giroglou T; Cinatl J; Rabenau H; Drosten C; Schwalbe H; Doerr HW; von Laer D
    J Virol; 2004 Sep; 78(17):9007-15. PubMed ID: 15308697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring Neutralizing Antibodies to SARS-CoV-2 Using Lentiviral Spike-Pseudoviruses.
    Neerukonda SN; Vassell R; Weiss CD; Wang W
    Methods Mol Biol; 2022; 2452():305-314. PubMed ID: 35554914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay.
    Zeng C; Evans JP; Pearson R; Qu P; Zheng YM; Robinson RT; Hall-Stoodley L; Yount J; Pannu S; Mallampalli RK; Saif L; Oltz E; Lozanski G; Liu SL
    medRxiv; 2020 Aug; ():. PubMed ID: 32793931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting.
    Millet JK; Tang T; Nathan L; Jaimes JA; Hsu HL; Daniel S; Whittaker GR
    J Vis Exp; 2019 Mar; (145):. PubMed ID: 30882796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a hybrid alphavirus-SARS-CoV-2 pseudovirion for rapid quantification of neutralization antibodies and antiviral drugs.
    Hetrick B; Chilin LD; He S; Dabbagh D; Alem F; Narayanan A; Luchini A; Li T; Liu X; Copeland J; Pak A; Cunningham T; Liotta L; Petricoin EF; Andalibi A; Wu Y
    Cell Rep Methods; 2022 Mar; 2(3):100181. PubMed ID: 35229082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.